<div class="govuk-grid-row">
  <div class="govuk-grid-column-two-thirds">
    <div class="gem-c-title govuk-!-margin-top-8 govuk-!-margin-bottom-8">
    <span class="govuk-caption-xl gem-c-title__context">
      Guidance
    </span>
  <h1 class="gem-c-title__text gem-c-title__text--long">
    Conditional Marketing Authorisations, exceptional circumstances Marketing Authorisations and national scientific advice from 1 January 2021
  </h1>
</div>
  </div>
  
  <div class="govuk-grid-column-two-thirds">
    
  <p class="gem-c-lead-paragraph">Guidance on Conditional Marketing Authorisations, exceptional circumstances Marketing Authorisations and national scientific advice from 1 January 2021.</p>

  </div>
</div>

<div class="govuk-grid-row">
  <div class="metadata-logo-wrapper">
    <div class="govuk-grid-column-two-thirds metadata-column">
        <div class="app-c-publisher-metadata" lang="en">
    <div class="app-c-published-dates " lang="en">
    Published 1 September 2020
</div>

      <div class="app-c-publisher-metadata__other">
        <dl data-module="track-click">
            <dt class="app-c-publisher-metadata__term">
              From:
            </dt>
            <dd class="app-c-publisher-metadata__definition" data-module="gem-toggle">
                <span class="app-c-publisher-metadata__definition-sentence">
                  <a class="govuk-link" href="/government/organisations/medicines-and-healthcare-products-regulatory-agency">Medicines and Healthcare products Regulatory Agency</a>
                </span>
            </dd>
        </dl>
      </div>
  </div>

    </div>
    <div class="govuk-grid-column-one-third">
    </div>
  </div>
</div>



  <section class="app-c-header-notice" aria-label="notice" role="region">
    <div class="app-c-header-notice__header">
      <h2 class="app-c-header-notice__title">New rules for January 2021</h2>
    </div>

    <div class="app-c-header-notice__content">
          <p class="app-c-header-notice__text govuk-body">The UK has left the EU, and the transition period after Brexit comes to an end this year.</p>
          <p class="app-c-header-notice__text govuk-body">This page tells you what you'll need to do from 1 January 2021. It will be updated if anything changes.</p>
        <div class="app-c-header-notice__links">
            <p class="govuk-body app-c-header-notice__link-intro">
              For current information, read: 
              <a data-module="track-click" data-track-category="no_deal_notice" data-track-action="/guidance/apply-for-a-licence-to-market-a-medicine-in-the-uk" data-track-label="Apply for a licence to market a medicine in the UK" class="app-c-header-notice__link" href="/guidance/apply-for-a-licence-to-market-a-medicine-in-the-uk">Apply for a licence to market a medicine in the UK</a>
            </p>
        </div>

        <p class="app-c-header-notice__text govuk-body">You can also read about <a data-module="track-click" data-track-category="no_deal_notice" data-track-action="/transition" data-track-label="the transition period" class="govuk-link" href="/transition">the transition period</a>.</p>
    </div>
  </section>


<div class="govuk-grid-row">
  <div class="govuk-grid-column-two-thirds">
    

      <div id="contents" class="app-c-contents-list-with-body" data-module="sticky-element-container">
      <div class="responsive-bottom-margin">
          <nav class="gem-c-contents-list  gem-c-contents-list--no-underline " role="navigation" data-module="track-click">
      <h2 class="gem-c-contents-list__title">Contents</h2>

    <ol class="gem-c-contents-list__list">
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 1" data-track-label="#guidance-for-great-britain-conditional-marketing-authorisation-applications" data-track-options="{"dimension29":"Guidance for Great Britain Conditional Marketing Authorisation Applications"}" href="#guidance-for-great-britain-conditional-marketing-authorisation-applications">Guidance for Great Britain Conditional Marketing Authorisation Applications</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 2" data-track-label="#guidance-for-great-britain-marketing-authorisations-under-exceptional-circumstances" data-track-options="{"dimension29":"Guidance for Great Britain Marketing Authorisations under exceptional circumstances"}" href="#guidance-for-great-britain-marketing-authorisations-under-exceptional-circumstances">Guidance for Great Britain Marketing Authorisations under exceptional circumstances</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 3" data-track-label="#guidance-for-national-scientific-advice-after-january-1-2021" data-track-options="{"dimension29":"Guidance for national scientific advice after January 1 2021"}" href="#guidance-for-national-scientific-advice-after-january-1-2021">Guidance for national scientific advice after January 1 2021</a>

        </li>
    </ol>
</nav>
      </div>
    
      
<div class="gem-c-govspeak govuk-govspeak direction-ltr" data-module="govspeak">
      <div class="govspeak">
<h2 id="guidance-for-great-britain-conditional-marketing-authorisation-applications">Guidance for Great Britain Conditional Marketing Authorisation Applications</h2>

<p>The <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> will introduce a national Conditional Marketing Authorisation (<abbr title="Conditional Marketing Authorisation">CMA</abbr>) scheme for new medicinal products in Great Britain from 1 January 2021. Great Britain is England, Wales and Scotland. In Northern Ireland Marketing Authorisation applications for products which fall within mandatory scope of the Centrally Authorised Procedure as laid down in Regulation (EC) No 726/2004, must be submitted to the <abbr title="European Medicines Agency">EMA</abbr>.</p>

<p>The scheme will have the same eligibility criteria as the <abbr title="European Union">EU</abbr> scheme and is intended for medicinal products that fulfill an unmet medical need. Examples would be for serious and life-threatening diseases where no satisfactory treatment methods are available or where the product offers a major therapeutic advantage.</p>

<p>The <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> may grant a <abbr title="Conditional Marketing Authorisation">CMA</abbr> where comprehensive clinical data is not yet complete, but it is judged that such data will become available soon.</p>

<h3 id="actions-for-those-submitting-a-marketing-authorisation-application-maa">Actions for those submitting a Marketing Authorisation Application (<abbr title="Marketing Authorisation Application">MAA</abbr>)</h3>

<p>The <abbr title="Marketing Authorisation Application">MAA</abbr> must still contain adequate evidence of safety and efficacy to enable the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> to conclude that the risk-benefit balance of the medicinal product is positive.</p>

<p>Applicants wishing to submit an application for a conditional marketing authorisation to the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> should state their justification for a <abbr title="Conditional Marketing Authorisation">CMA</abbr> and indicate clearly what clinical studies are underway and when comprehensive clinical data will become available.</p>

<p>Eligibility for a <abbr title="Conditional Marketing Authorisation">CMA</abbr> will be determined by the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> at the time of <abbr title="Marketing Authorisation Application">MAA</abbr> assessment.</p>

<p>There is no specific application route for a <abbr title="Conditional Marketing Authorisation">CMA</abbr>; applicants should submit their <abbr title="Marketing Authorisation Application">MAA</abbr> dossier as for a full Marketing Authorisation.</p>

<p>At the completion of the assessment of a <abbr title="Marketing Authorisation Application">MAA</abbr> dossier, the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> will determine whether to approve the application and grant a conditional MA or whether the risk benefit ratio is negative and reject the application.</p>

<p>The designation of a product as being eligible for a <abbr title="Conditional Marketing Authorisation">CMA</abbr> by the <abbr title="European Medicines Agency">EMA</abbr> or another jurisdiction may be taken into account by the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr>, but the final decision on eligibility of the product for the Great Britain scheme will rest with <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr>.</p>

<p><abbr title="Conditional Marketing Authorisations">CMAs</abbr> will be valid for one year and will be renewable annually.</p>

<h2 id="guidance-for-great-britain-marketing-authorisations-under-exceptional-circumstances">Guidance for Great Britain Marketing Authorisations under exceptional circumstances</h2>

<p>The <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr>â€™s existing scheme for applications under exceptional circumstances will continue to be available for medicines where a comprehensive data package cannot be provided, because the condition to be treated is rare or because collection of full information is not possible or is unethical. Applications for Marketing Authorisations under Exceptional Circumstances in Northern Ireland must be submitted to the <abbr title="European Medicines Agency">EMA</abbr>.</p>

<p>This is covered under <a rel="external" href="http://www.legislation.gov.uk/uksi/2012/1916/regulation/60" class="govuk-link">Human Medicines Regulations 2012, Regulation 60, â€˜Conditions of UK marketing authorisation: exceptional circumstancesâ€™</a>.</p>

<p>The scheme has the same eligibility criteria as the <abbr title="European Union">EU</abbr> scheme. Approvals will only be granted under this scheme where there are exceptional circumstances and where the applicant can demonstrate that it is not possible to provide comprehensive data on the efficacy and safety under normal conditions of use.</p>

<p>The designation of a product as being eligible for an exceptional circumstances scheme by the <abbr title="European Medicines Agency">EMA</abbr> or another jurisdiction may be taken into account by the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr>, but the final decision on eligibility of the product for the GB scheme will rest with <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr>.</p>

<h3 id="actions-for-those-applying-for-uk-marketing-authorisations-under-exceptional-circumstances">Actions for those applying for UK marketing authorisations under exceptional circumstances</h3>

<p>The <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> is likely to impose specific obligations on the holder of a Marketing Authorisation that is approved under exceptional circumstances. These will be communicated to the applicant during the review and will be aimed at the provision of information on the safe and effective use of the product.</p>

<p>Applicants are required to discuss their submissions with the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> prior to submitting their Marketing Authorisation Application.</p>

<h2 id="guidance-for-national-scientific-advice-after-january-1-2021">Guidance for national scientific advice after January 1 2021</h2>

<p>The <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> will continue to offer its national scientific advice service after 1 January 2021. This service is available for developers of medicinal products and can be requested at any stage of the productâ€™s development. The procedure for requesting scientific advice is <a href="https://www.gov.uk/guidance/medicines-get-scientific-advice-from-mhra" class="govuk-link">described in further detail</a>.</p>

<p>From 1 January 2021 there will be one change to the fees payable for scientific advice. Applications for scientific advice submitted by UK-based Small and Medium-sized Enterprises (<abbr title="Small and Medium-sized Enterprises">SME</abbr>) will be exempt from the fee. Applicants will be required to submit evidence of their <abbr title="Small and Medium-sized Enterprises">SME</abbr> status together with the scientific advice form.</p>

<p>Requests for advice that is purely regulatory in nature will remain free of charge.</p>

<p>This guidance will apply from 1 January 2021.</p>

</div>
</div>


      <div class="responsive-bottom-margin">
        <div class="app-c-published-dates " lang="en">
    Published 1 September 2020
</div>

      </div>

      <div data-sticky-element class="app-c-contents-list-with-body__link-wrapper">
        <div class="app-c-contents-list-with-body__link-container">
          <a class="govuk-link app-c-back-to-top dont-print" href="#contents">
    <svg class="app-c-back-to-top__icon" xmlns="http://www.w3.org/2000/svg" width="13" height="17" viewbox="0 0 13 17">
      <path fill="currentColor" d="M6.5 0L0 6.5 1.4 8l4-4v12.7h2V4l4.3 4L13 6.4z"></path>
    </svg>
    Contents
</a>

        </div>
      </div>
  </div>
  </div>
  
<div class="govuk-grid-column-one-third">
  
<div class="gem-c-contextual-sidebar">
    <div class="gem-c-contextual-sidebar__brexit-cta govuk-!-margin-bottom-6" data-module="track-click">
  <h2 class="gem-c-contextual-sidebar__brexit-heading">Transition period</h2>
  <a href="/transition" class="govuk-link" data-track-category="relatedLinkClicked" data-track-action="1.0 Transition" data-track-label="/transition" data-track-options="{"dimension29":"Find out what it means for you"}">Find out what it means for you</a>
</div>



    
  <div class="gem-c-related-navigation">

      <h2 id="related-nav-related_items-0eea8be2" class="gem-c-related-navigation__main-heading" data-track-count="sidebarRelatedItemSection">
        Related content
      </h2>




      <nav role="navigation" class="gem-c-related-navigation__nav-section" aria-labelledby="related-nav-collections-0eea8be2" data-module="gem-toggle">

    <h3 id="related-nav-collections-0eea8be2" class="gem-c-related-navigation__sub-heading gem-c-related-navigation__sub-heading--sidebar" data-track-count="sidebarRelatedItemSection">Collection</h3>

  <ul class="gem-c-related-navigation__link-list" data-module="track-click">


        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--sidebar" data-track-category="relatedLinkClicked" data-track-action="1.1 Collection" data-track-label="/government/collections/mhra-post-transition-period-information" data-track-options="{"dimension28":"1","dimension29":"MHRA post-transition period information"}" href="/government/collections/mhra-post-transition-period-information">MHRA post-transition period information</a></li>

  </ul>
</nav>

  </div>



</div>

</div>

</div>


  <div class="govuk-grid-row">
    <div class="govuk-grid-column-two-thirds">
        
  <div class="gem-c-contextual-footer">
    
  <div class="gem-c-related-navigation">





      <nav role="navigation" class="gem-c-related-navigation__nav-section" aria-labelledby="related-nav-topics-62f3fae7" data-module="gem-toggle">

    <h2 id="related-nav-topics-62f3fae7" class="gem-c-related-navigation__sub-heading gem-c-related-navigation__sub-heading--footer" data-track-count="footerRelatedItemSection">Explore the topic</h2>

  <ul class="gem-c-related-navigation__link-list" data-module="track-click">


        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--footer" data-track-category="relatedLinkClicked" data-track-action="1.1 Explore the topic" data-track-label="/topic/medicines-medical-devices-blood/marketing-authorisations-variations-licensing" data-track-options="{"dimension28":"1","dimension29":"Marketing authorisations, variations and licensing guidance"}" href="/topic/medicines-medical-devices-blood/marketing-authorisations-variations-licensing">Marketing authorisations, variations and licensing guidance</a></li>

  </ul>
</nav>

  </div>

  </div>


    </div>
  </div>